EBR Systems (ASX:EBR) said the US Centers for Medicare & Medicaid Services provided preliminary approval for the transitional pass-through reimbursement scheme for the firm's proprietary Wireless Stimulation Endocardially cardiac resynchronization therapy system, according to a Tuesday Australian bourse filing.
The preliminary approval is expected to become effective in October and will be effective for three years.
The firm said it will continue to engage with the agency through the upcoming annual rulemaking and public comment process.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.